Загрузка...
Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
Hydroxyurea is the sole approved pharmacologic therapy for sickle cell disease (SCD). Higher fetal hemoglobin (HbF) levels diminish de-oxygenated sickle globin polymerization in vitro and clinically reduce the incidence of disease morbidities. Clinical and laboratory effects of hydroxyurea largely r...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3917141/ https://ncbi.nlm.nih.gov/pubmed/24252885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pr.2013.227 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|